Improve walking balance and thinking
- Trial ID
- NCT06868160
- Official Title
- Neurotech PD Gait: Multisite Non-invasive Electrical Stimulation to Optimize Motor-cognitive Rehabilitation Response in Parkinson's Disease Subjects With Postural Instability and Gait Disorders
- Goal
- Improve walking balance and thinking
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- IRCCS San Raffaele
- Study Type
- INTERVENTIONAL
- Enrollment
- 71 participants
- Conditions
- Parkinson Disease
- Interventions
- Rehabilitation, SHAM tDCS, tDCS, tsDCS (first cycle), tsDCS (second cycle), SHAM tsDCS (first cycle), SHAM tsDCS (second cycle), SHAM tsDCS
Plain-Language Summary
The goal is to help people with Parkinson's who have postural instability and gait problems improve walking, balance, and the motor-cognitive benefits they get from rehabilitation. The approach pairs painless, low-intensity direct currents to the scalp (tDCS) and over the spinal cord (tsDCS) with rehab exercises, aiming to boost brain and spinal circuit excitability so motor learning and sensorimotor control stick better; sessions include sham controls and the intervention is tested as an add-on while participants remain on stable dopaminergic medication. They are looking for adults 45 to 85 with idiopathic PD of the PIGD type, Hoehn and Yahr stage up to 4, no dementia (MMSE ≥24), stable dopaminergic therapy for at least 4 weeks, and no MRI contraindications or implanted neurostimulation devices.
Locations
- San Raffaele Neurotech Hub, Milan, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Rehabilitation. The goal is to help people with Parkinson's who have postural instability and gait problems improve walking, balance, and the motor-cognitive benefits they get from rehabilitation. The approach pairs painless, low-intensity direct currents to the scalp (tDCS) and over the spinal cord (tsDCS) with rehab exercises, aiming to boost brain and spinal circuit excitability so motor learning and sensorimotor control stick better; sessions include sham controls and the intervention is tested as an add-on while participants remain on stable dopaminergic medication. They are looking for adults 45 to 85 with idiopathic PD of the PIGD type, Hoehn and Yahr stage up to 4, no dementia (MMSE ≥24), stable dopaminergic therapy for at least 4 weeks, and no MRI contraindications or implanted neurostimulation devices.
- Who can participate?
- Participants must be between 45 Years and 85 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years.